Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.35 |
| ▸ | PYGL | P06737 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2515799 | 1.00 | CA2 (0.42) | CA2MAPTKDM4ETHRBRECQL | |
| SCHEMBL1236539 | 1.00 | CA2 (0.42) | CA2MAPTKDM4ETHRBRECQL | |
| SCHEMBL8357912 | 0.82 | CA2 (0.43) | CA2MAPTTHRBRECQLALDH1A1 | |
| SCHEMBL883447 | 0.82 | CA2 (0.43) | CA2MAPTTHRBRECQLALDH1A1 | |
| SCHEMBL12965979 | 0.82 | ADAM17 (0.36) | CA2MAPTKDM4ETHRBRECQL | |
| SCHEMBL23155068 | 0.82 | ADAM17 (0.36) | CA2MAPTKDM4ETHRBRECQL | |
| SCHEMBL25893507 | 0.81 | KDM4E (0.39) | CA2MAPTKDM4ETHRBRECQL | |
| N-Acetyl Penicillamine SCHEMBL4468919 | 0.81 | MAPT (0.43) | CA2MAPTKDM4ETHRBRECQL | |
| N-Acetyl Penicillamine SCHEMBL521764 | 0.81 | MAPT (0.43) | CA2MAPTKDM4ETHRBRECQL | |
| N-Acetyl Penicillamine SCHEMBL34351 | 0.81 | MAPT (0.43) | CA2MAPTKDM4ETHRBRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9095620-B2 | Reagents | NEKTAR THERAPEUTICS (US) | 2015-08-04 | — | — | US | disclosed |
| US-20130005780-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF TAPENTADOL | LUPIN LIMITED (IN) | 2013-01-03 | — | — | US | disclosed |
| US-8093231-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110071093-A1 | Novel Reagents | NEKTAR THERAPEUTICS (US) | 2011-03-24 | — | — | US | disclosed |
| US-20100184989-A1 | De Novo Synthesis of Conjugates | NEKTAR THERAPEUTICS (US) | 2010-07-22 | — | — | US | disclosed |
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | TELIK, INC. | 2008-02-14 | — | — | US | disclosed |
| US-7262182-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| EP-0759475-B1 | Method for the production of (R)-ter-leucine | DEGUSSA (DE) | 1999-08-25 | — | — | EP | disclosed |
| US-5707837-A | Method of producing (R)-tertiary leucine | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1998-01-13 | — | — | US | disclosed |
| EP-0759475-A1 | Method for the production of (R)-ter-leucine | DEGUSSA AG (DE) | 1997-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071093-A1 | Novel Reagents | DNPEP, NGLY1, COG7 | CA2 3546/4885MAPT 443/4885KDM4E 4837/4885 |
| US-20130005780-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF TAPENTADOL | TPMT, NSUN3, SLC43A1 | CA2 2783/4885MAPT 273/4885KDM4E 1042/4885 |
| US-20100184989-A1 | De Novo Synthesis of Conjugates | ABCG2, UGT1A8, SLC7A5 | CA2 4454/4885MAPT 81/4885KDM4E 4261/4885 |
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | MTAP, TYMP, PHOSPHO1 | CA2 3159/4885MAPT 3626/4885KDM4E 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.